These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 26959365

  • 1. The Dose-Dependent Organ-Specific Effects of a Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Complications in a Model of Type 2 Diabetes.
    Moon JY, Woo JS, Seo JW, Lee A, Kim DJ, Kim YG, Kim SY, Lee KH, Lim SJ, Cheng XW, Lee SH, Kim W.
    PLoS One; 2016; 11(3):e0150745. PubMed ID: 26959365
    [Abstract] [Full Text] [Related]

  • 2. Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy.
    Jung E, Kim J, Ho Kim S, Kim S, Cho MH.
    Eur J Pharmacol; 2015 Aug 15; 761():116-24. PubMed ID: 25977232
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
    Kim SH, Jung E, Yoon MK, Kwon OH, Hwang DM, Kim DW, Kim J, Lee SM, Yim HJ.
    Eur J Pharmacol; 2016 Oct 05; 788():54-64. PubMed ID: 27298192
    [Abstract] [Full Text] [Related]

  • 4. Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice.
    Choi SH, Leem J, Lee IK.
    Mediators Inflamm; 2017 Oct 05; 2017():4139439. PubMed ID: 29317794
    [Abstract] [Full Text] [Related]

  • 5. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
    Han SY, Yoon SA, Han BG, Kim SG, Jo YI, Jeong KH, Oh KH, Park HC, Park SH, Kang SW, Na KR, Kang SW, Kim NH, Jang Y, Kim B, Shin S, Cha DR.
    Diabetes Obes Metab; 2018 Feb 05; 20(2):292-300. PubMed ID: 28719008
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Gemigliptin Attenuates Renal Fibrosis Through Down-Regulation of the NLRP3 Inflammasome.
    Seo JB, Choi YK, Woo HI, Jung YA, Lee S, Lee S, Park M, Lee IK, Jung GS, Park KG.
    Diabetes Metab J; 2019 Dec 05; 43(6):830-839. PubMed ID: 30877711
    [Abstract] [Full Text] [Related]

  • 9. Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized Controlled Trial.
    Trakarnvanich T, Satirapoj B, Suraamornkul S, Chirananthavat T, Sanpatchayapong A, Claimon T.
    J Diabetes Res; 2021 Dec 05; 2021():7382620. PubMed ID: 34697593
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The dipeptidyl peptidase-IV inhibitor inhibits the expression of vascular adhesion molecules and inflammatory cytokines in HUVECs via Akt- and AMPK-dependent mechanisms.
    Hwang HJ, Chung HS, Jung TW, Ryu JY, Hong HC, Seo JA, Kim SG, Kim NH, Choi KM, Choi DS, Baik SH, Yoo HJ.
    Mol Cell Endocrinol; 2015 Apr 15; 405():25-34. PubMed ID: 25661535
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Dipeptidyl peptidase-4 inhibition by gemigliptin prevents abnormal vascular remodeling via NF-E2-related factor 2 activation.
    Choi SH, Park S, Oh CJ, Leem J, Park KG, Lee IK.
    Vascul Pharmacol; 2015 Oct 15; 73():11-9. PubMed ID: 26187356
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study).
    Lim S, Han KA, Yu J, Chamnan P, Kim ES, Yoon KH, Kwon S, Moon MK, Lee KW, Kim DJ, Kim M, Wongtanate M, Kim EY, Kim SH, Lee MK, INICOM Study Group.
    Diabetes Obes Metab; 2017 Jan 15; 19(1):87-97. PubMed ID: 27619558
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Dipeptidyl peptidase-4 inhibitor gemigliptin protects against vascular calcification in an experimental chronic kidney disease and vascular smooth muscle cells.
    Choi SY, Ryu HM, Oh EJ, Choi JY, Cho JH, Kim CD, Kim YL, Park SH.
    PLoS One; 2017 Jan 15; 12(7):e0180393. PubMed ID: 28686724
    [Abstract] [Full Text] [Related]

  • 17. Effects of gemigliptin, a dipeptidyl peptidase-4 inhibitor, on lipid metabolism and endotoxemia after a high-fat meal in patients with type 2 diabetes.
    Ahn CH, Kim EK, Min SH, Oh TJ, Cho YM.
    Diabetes Obes Metab; 2017 Mar 15; 19(3):457-462. PubMed ID: 27868366
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects.
    Shin D, Cho YM, Lee S, Lim KS, Kim JA, Ahn JY, Cho JY, Lee H, Jang IJ, Yu KS.
    Clin Drug Investig; 2014 Jun 15; 34(6):383-93. PubMed ID: 24627290
    [Abstract] [Full Text] [Related]

  • 19. A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes.
    Yang SJ, Min KW, Gupta SK, Park JY, Shivane VK, Pitale SU, Agarwal PK, Sosale A, Gandhi P, Dharmalingam M, Mohan V, Mahesh U, Kim DM, Kim YS, Kim JA, Kim PK, Baik SH.
    Diabetes Obes Metab; 2013 May 15; 15(5):410-6. PubMed ID: 23170990
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.